scholarly journals Adjuvant immunotherapy versus tyrosine kinase inhibitors in patients with high-risk renal cell carcinoma: A systematic review and network meta-analysis of oncologic and toxicity outcomes

2021 ◽  
Vol 33 ◽  
pp. S333-S334
Author(s):  
E. Laukhtina ◽  
F. Quhal ◽  
K. Mori ◽  
R. Sari Motlagh ◽  
S. Katayama ◽  
...  
Keyword(s):  
Systematic Review ◽  
Renal Cell Carcinoma ◽  
High Risk ◽  
Tyrosine Kinase ◽  
Cell Carcinoma ◽  
Tyrosine Kinase Inhibitors ◽  
Renal Cell ◽  
Kinase Inhibitors ◽  
Meta Analysis ◽  
Adjuvant Immunotherapy

The merit of tyrosine kinase inhibitors in the adjuvant setting of high-risk renal cell carcinoma: a meta-analysis

2018 ◽  
Vol 14 (9) ◽  
pp. 829-835 ◽  
Author(s):  
Hampig Raphael Kourie ◽  
Ziad Bakouny ◽  
Roland Eid ◽  
Fady GH Haddad ◽  
Joseph Kattan
Keyword(s):  
Renal Cell Carcinoma ◽  
High Risk ◽  
Tyrosine Kinase ◽  
Cell Carcinoma ◽  
Tyrosine Kinase Inhibitors ◽  
Renal Cell ◽  
Kinase Inhibitors ◽  
Meta Analysis ◽  
Adjuvant Setting

Adjuvant Tyrosine Kinase Inhibitors in Treatment of Renal Cell Carcinoma: A Meta-Analysis of Available Clinical Trials

2019 ◽  
Vol 17 (2) ◽  
pp. e339-e344 ◽  
Author(s):  
Francesco Massari ◽  
Vincenzo Di Nunno ◽  
Veronica Mollica ◽  
Jeffrey Graham ◽  
Lidia Gatto ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Clinical Trials ◽  
Tyrosine Kinase ◽  
Cell Carcinoma ◽  
Tyrosine Kinase Inhibitors ◽  
Renal Cell ◽  
Kinase Inhibitors ◽  
Meta Analysis

scholarly journals Tyrosine kinase inhibitors–induced hypothyroidism as a prognostic factor in metastatic renal cell carcinoma: a systematic review and meta-analysis

2020 ◽  
Author(s):  
Li Bo ◽  
Liang Zhou ◽  
Yin Tang ◽  
Yu Liu ◽  
Kunjie Wang ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Tyrosine Kinase ◽  
Cell Carcinoma ◽  
Tyrosine Kinase Inhibitors ◽  
Publication Bias ◽  
Renal Cell ◽  
Kinase Inhibitors ◽  
Meta Analysis ◽  
Progression Free Survival ◽  
Free Survival

Abstract Background: Hypothyroidism as a predictive factor represent highly controversial in patients with metastatic renal cell carcinoma (mRCC) with tyrosine kinase inhibitors-induced (TKI-induced) hypothyroidism. we aimed to evaluate the predictive value of TKI-induced hypothyroidism for progression-free survival (PFS) in patients with mRCC.Methods: PubMed, Web of Science and Cochrane Library databases were searched with the keywords of "renal cell carcinoma", "hypothyroidism", "tyrosine kinase inhibitor", "sunitinib", "axitinib", "sorafenib" and "pazopanib" until September 2019. The hazard ratio (HR) and 95% confidence interval (CI) of extracted from progression-free survival (PFS) were statistically analyzed by STATA15.1 software. Heterogeneity was assessed by I²value. Publication bias was appraised by the funnel chart, Egger's and Begg's tests.Results: Eighteen studies with more than 1300 patients were included in this meta-analysis. The result demonstrated that TKI-induced hypothyroidism was an effective predictor of longer PFS (HR=0.57,95%CI:0.49-0.66, P＜0.001, I²=34.4%) in patients with mRCC. No significant publication bias was detected.Conclusions: Our analysis harvested from currently available clinical evidence shows that TKI-induced hypothyroidism expressed longer PFS, compared with euthyroidism, among patients with mRCC treated with "sunitinib", "axitinib", "sorafenib" and "pazopanib".

scholarly journals Tyrosine kinase inhibitors–induced hypothyroidism as a prognostic factor in metastatic renal cell carcinoma: a systematic review and meta-analysis

2020 ◽  
Author(s):  
Li Bo ◽  
Liang Zhou ◽  
Yin Tang ◽  
Yu Liu ◽  
Hong Li ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Tyrosine Kinase ◽  
Cell Carcinoma ◽  
Tyrosine Kinase Inhibitors ◽  
Publication Bias ◽  
Renal Cell ◽  
Kinase Inhibitors ◽  
Meta Analysis ◽  
Progression Free Survival ◽  
Free Survival

Abstract Background Hypothyroidism as a predictive factor represent highly controversial in patients with metastatic renal cell carcinoma (mRCC) with tyrosine kinase inhibitors-induced (TKI-induced) hypothyroidism. we aimed to evaluate the predictive value of TKI-induced hypothyroidism for progression-free survival (PFS) in patients with mRCC. Methods PubMed, Web of Science and Cochrane Library databases were searched with the keywords of "renal cell carcinoma", "hypothyroidism", "tyrosine kinase inhibitor", "sunitinib", "axitinib", "sorafenib" and "pazopanib" until September 2019. The hazard ratio (HR) and 95% confidence interval (CI) of extracted from progression-free survival (PFS) were statistically analyzed by STATA15.1 software. Heterogeneity was assessed by I²value. Publication bias was appraised by the funnel chart, Egger's and Begg's tests. Results Eighteen studies with more than 1300 patients were included in this meta-analysis. The result demonstrated that TKI-induced hypothyroidism was an effective predictor of longer PFS (HR = 0.57,95%CI:0.49–0.66, P༜0.001, I²=34.4%) in patients with mRCC. No significant publication bias was detected. Conclusions Our analysis harvested from currently available clinical evidence shows that TKI-induced hypothyroidism expressed longer PFS, compared with euthyroidism, among patients with mRCC treated with "sunitinib", "axitinib", "sorafenib" and "pazopanib".

Sign in / Sign up

Export Citation Format

Share Document